Drugs / BI-1206
BI-1206
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04219254 | Jun 2020 → Nov 2027 expected | cancer | BioInvent International AB | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03571568 | May 2018 → Sep 2026 expected | indolent B-cell non-Hodgkin lymphoma | BioInvent International AB | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02933320 | Oct 2016 → Mar 2020 | B-cell chronic lymphocytic leukemia, Waldenstrom macroglobulinemia | Cancer Research UK | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI1206 | “BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB)” NCT04219254 ↗ |
| Known as | 6G11 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594465 ↗ |
| Known as | Anti-hfcgammariib mab bi-1206 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594465 ↗ |
| Action | Deplete | “is thought to act by recruiting host immune cells toward the tumour leading to cancer cell death” NCT02933320 ↗ |
| Modality | Monoclonal antibody | “BI-1206, is an anti-CD32b monoclonal antibody” NCT02933320 ↗ |
| Route | Intravenous | “BI-1206 given by IV infusion” NCT02933320 ↗ |